Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxychloroquine Pre-exposure Prophylaxis for COVID-19 in Healthcare Workers
NCT04374942Phase 3Terminated
- Start
- Apr 2020
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of hydroxychloroquine in coronavirus disease 2019 (COVID-19) (2 arms). Primary endpoint: Microbiologically confirmed COVID-19 (SARS-CoV-2 infection) at Day 120. Started Apr 2020; status: terminated.
02
Drugs
hydroxychloroquine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04374942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04374942.